Nifty
Sensex
:
:
11987.65
40648.47
-11.45 (-0.10%)
-3.17 (-0.01%)

Pharmaceuticals & Drugs

Rating :
62/99  (View)

BSE: 500087 | NSE: CIPLA

487.65
5.05 (1.05%)
21-Nov-2019 | 12:04PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  482.60
  •  492.30
  •  476.60
  •  482.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3677587
  •  17933.75
  •  586.00
  •  389.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 38,912.46
  • 23.60
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 42,609.88
  • 0.62%
  • 2.50

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.68%
  • 3.22%
  • 16.20%
  • FII
  • DII
  • Others
  • 0.96%
  • 17.03%
  • 25.91%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.81
  • 7.60
  • 4.36

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.33
  • 5.82
  • 2.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.62
  • 5.08
  • 15.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.14
  • 36.08
  • 36.59

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.64
  • 3.69
  • 3.28

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.13
  • 17.96
  • 16.51

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Net Sales
4,395.78
4,011.90
9.57%
3,989.02
3,938.99
1.27%
4,403.98
3,697.97
19.09%
4,007.54
3,913.82
2.39%
Expenses
3,486.28
3,309.68
5.34%
3,084.38
3,212.62
-3.99%
3,442.93
3,141.10
9.61%
3,299.87
3,095.16
6.61%
EBITDA
909.50
702.22
29.52%
904.64
726.37
24.54%
961.05
556.87
72.58%
707.67
818.66
-13.56%
EBIDTM
20.69%
17.50%
22.68%
18.44%
21.82%
15.06%
17.66%
20.92%
Other Income
100.52
132.57
-24.18%
78.37
170.11
-53.93%
95.36
40.01
138.34%
78.53
52.93
48.37%
Interest
46.07
44.37
3.83%
52.12
35.09
48.53%
44.78
35.20
27.22%
44.19
9.15
382.95%
Depreciation
282.96
281.90
0.38%
268.00
241.00
11.20%
510.28
284.82
79.16%
293.13
522.35
-43.88%
PBT
680.99
508.52
33.92%
662.89
620.39
6.85%
501.35
199.34
151.50%
448.88
340.09
31.99%
Tax
200.55
142.39
40.85%
192.24
173.71
10.67%
127.75
46.15
176.81%
125.68
-64.23
-
PAT
480.44
366.13
31.22%
470.65
446.68
5.37%
373.60
153.19
143.88%
323.20
404.32
-20.06%
PATM
10.93%
9.13%
11.80%
11.34%
8.48%
4.14%
8.06%
10.33%
EPS
5.85
4.68
25.00%
5.93
5.60
5.89%
4.56
2.22
105.41%
4.12
4.98
-17.27%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
16,796.32
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
5,359.52
Net Sales Growth
7.93%
7.96%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
17.99%
 
Cost Of Goods Sold
5,605.99
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
2,452.98
Gross Profit
11,190.33
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
2,906.54
GP Margin
66.62%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
54.23%
Total Expenditure
13,313.46
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
4,286.56
Power & Fuel Cost
-
335.11
298.82
251.73
245.92
228.28
218.63
233.12
235.35
198.55
92.15
% Of Sales
-
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
1.72%
Employee Cost
-
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
289.59
% Of Sales
-
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
5.40%
Manufacturing Exp.
-
1,284.94
1,220.67
1,192.77
1,596.79
737.11
644.42
541.58
583.18
627.94
708.39
% Of Sales
-
7.85%
8.05%
8.29%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
13.22%
General & Admin Exp.
-
1,096.50
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
288.71
231.05
% Of Sales
-
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
4.31%
Selling & Distn. Exp.
-
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
326.48
% Of Sales
-
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
6.09%
Miscellaneous Exp.
-
855.40
968.98
645.54
83.99
497.67
441.10
355.12
194.07
111.96
326.48
% Of Sales
-
5.23%
6.39%
4.48%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
3.47%
EBITDA
3,482.86
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
1,072.96
EBITDA Margin
20.74%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
20.02%
Other Income
352.78
476.57
357.65
228.69
208.21
165.55
265.37
222.14
139.52
91.68
353.50
Interest
187.16
168.43
114.23
159.38
206.63
168.29
145.74
33.91
38.34
25.10
28.30
Depreciation
1,354.37
1,097.15
949.83
1,322.93
754.22
504.71
372.64
330.48
312.22
273.33
167.07
PBT
2,294.11
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
1,231.09
Tax
646.22
569.53
250.11
179.76
331.59
400.03
463.38
544.31
306.51
195.22
243.50
Tax Rate
28.17%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
18.36%
PAT
1,647.89
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
1,082.59
PAT before Minority Interest
1,695.26
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
1,082.59
Minority Interest
47.37
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
0.00
PAT Margin
9.81%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
20.20%
PAT Growth
20.26%
9.31%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
-10.65%
 
Unadjusted EPS
20.46
18.97
17.53
12.52
16.93
14.71
17.29
19.24
14.25
12.32
13.70

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
5,910.57
Share Capital
161.14
161.02
160.90
160.68
160.59
160.58
160.58
160.58
160.58
160.58
Total Reserves
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
5,749.99
Non-Current Liabilities
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
184.22
Secured Loans
47.70
0.00
0.00
207.00
287.09
317.44
0.00
0.00
15.00
0.41
Unsecured Loans
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
4.66
Long Term Provisions
121.41
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
0.00
Current Liabilities
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
2,525.63
Trade Payables
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
720.88
805.41
Other Current Liabilities
541.86
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
235.28
192.56
Short Term Borrowings
486.16
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
0.00
Short Term Provisions
795.50
630.19
426.43
324.42
382.04
264.91
232.00
221.29
219.32
1,527.66
Total Liabilities
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
Net Block
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
2,011.17
Gross Block
13,665.08
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
2,897.26
Accumulated Depreciation
4,108.55
3,010.87
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
886.09
Non Current Assets
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
2,696.41
Capital Work in Progress
676.18
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
684.24
Non Current Investment
490.20
157.66
137.36
176.35
249.76
397.14
415.69
328.59
367.18
1.00
Long Term Loans & Adv.
455.57
514.96
543.67
426.18
1,860.78
1,552.40
978.96
865.38
841.20
0.00
Other Non Current Assets
166.82
255.71
210.06
176.54
168.39
151.74
154.88
38.95
30.98
0.00
Current Assets
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
5,924.01
Current Investments
2,125.79
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
245.41
Inventories
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
1,512.58
Sundry Debtors
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
1,566.63
Cash & Bank
618.81
965.61
638.27
871.40
564.26
175.76
143.01
90.46
95.97
62.06
Other Current Assets
1,566.48
480.20
418.17
437.05
858.67
630.63
468.31
622.17
726.59
2,537.33
Short Term Loans & Adv.
1,150.49
1,118.93
807.84
786.12
713.07
595.13
463.21
459.94
533.77
2,387.57
Net Current Assets
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
3,398.38
Total Assets
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
1,043.03
PBT
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
1,326.09
Adjustment
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
283.82
396.66
288.84
146.53
Changes in Working Capital
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
-173.82
Cash after chg. in Working capital
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
1,298.80
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
-255.77
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
-562.75
Net Fixed Assets
-173.15
-509.84
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
-520.07
Net Investments
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
-183.78
Others
-255.79
6.92
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
141.10
Cash from Financing Activity
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
-471.61
Net Cash Inflow / Outflow
-326.26
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
8.67
Opening Cash & Equivalents
853.47
610.35
858.15
545.84
175.76
143.01
90.46
95.97
62.06
53.39
Closing Cash & Equivalent
508.36
853.46
610.35
858.15
564.26
175.76
143.01
90.46
95.97
62.06

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
185.62
175.92
155.15
142.23
133.38
124.79
112.21
95.03
82.91
73.50
ROA
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
13.38%
ROE
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
21.14%
ROCE
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
24.22%
Fixed Asset Turnover
1.80
1.25
1.36
1.40
1.26
1.47
1.69
1.61
1.79
1.94
Receivable days
55.36
68.17
61.60
57.62
57.94
58.66
70.11
77.94
87.29
115.32
Inventory Days
61.13
90.71
91.41
100.43
106.36
93.68
92.19
96.16
97.61
98.17
Payable days
59.02
57.37
46.96
48.81
52.17
44.93
48.58
50.51
56.11
69.48
Cash Conversion Cycle
57.47
101.50
106.05
109.24
112.14
107.41
113.72
123.59
128.78
144.01
Total Debt/Equity
0.29
0.29
0.33
0.46
0.16
0.12
0.11
0.00
0.09
0.00
Interest Cover
13.34
15.61
8.67
9.36
10.83
13.90
62.79
38.76
47.31
47.86

News Update


  • USFDA completes routine cGMP inspection at Cipla’s Patalganga facility
    15th Nov 2019, 09:53 AM

    The inspection ended with 4 observations, none of which were repeat or related to data integrity

    Read More
  • Cipla reports 29% rise in Q2 consolidated net profit
    6th Nov 2019, 14:51 PM

    Total consolidated income of the company increased by 8.49% at Rs 4496.30 crore for Q2FY20

    Read More
  • Cipla - Quarterly Results
    6th Nov 2019, 14:06 PM

    Read More
  • Cipla acquires novel anti-infective Elores from Venus Remedies
    18th Oct 2019, 09:01 AM

    The company to further strengthen its presence in the branded Indian critical care space

    Read More
  • USFDA completes cGMP inspection at Cipla’s Goa facility
    30th Sep 2019, 09:51 AM

    The inspection ended with 12 observations, none of which are related to data integrity

    Read More
  • Cipla launches Daptomycin for Injection
    26th Sep 2019, 08:56 AM

    Cubicin for Injection had US sales of approximately $606 Million for the 12-month period ending June 2019

    Read More
  • Cipla receives EIR from USFDA for API facility in Bengaluru
    23rd Sep 2019, 09:46 AM

    The agency had conducted inspection at API manufacturing facility in Virgonagar

    Read More
  • Stempeutics Research signs out-licensing deal with Cipla
    17th Sep 2019, 10:43 AM

    The deal consists of upfront payment and various milestones-based payments

    Read More
  • Cipla gets shareholders’ nod to raise Rs 3,000 crore
    19th Aug 2019, 09:39 AM

    The company's board had approved raising funds up to Rs 3,000 crore

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.